CELZ

Business Context and Reporting Period

Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A commercial-stage biotechnology company focused on immunotherapy, endocrinology, urology, neurology, and orthopedics. The company operates primarily through its subsidiary, Creative Medical Technologies, Inc. (CMT), marketing disposable kits for erectile and female sexual dysfunction. It is also developing stem cell-based therapies (ImmCelz, StemSpine, AlloCelz) for conditions including Type 1 Diabetes and chronic lower back pain.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue was $0 for the quarter ended June 30, 2025, compared to $8,000 in the prior year quarter. For the six-month period, revenue was $3,000 versus $8,000 in the prior year.
• Net Loss: The net loss for the quarter decreased to $(1,233,303) from $(1,557,728) in the prior year quarter. For the six-month period, the net loss increased to $(2,871,400) from $(2,599,272).
• Operating Expenses:
  • R&D: Decreased by 46% ($423,488) for the quarter due to timing of efforts with industry partners. For the six months, R&D decreased by 8% ($102,576), offset by increased spending on the AlloStemSpine clinical trial.
  • SG&A: Increased by 8% ($55,431) for the quarter and 20% ($272,344) for the six months, driven by higher marketing expenses, legal fees, and contract renewals.
• Other Income: Interest income decreased significantly due to lower short-term investment balances ($30,217 for the quarter vs. $67,578 prior year).
• Capital Structure: The company raised approximately $3.7 million in net proceeds in March 2025 through a warrant exercise inducement, increasing cash reserves significantly compared to the prior year.

Outlook, Risks, and Management Commentary

• Clinical Progress:
  • CELZ-201 ADAPT (Lower Back Pain): Completed dosing of the second cohort (20 patients total) in Q2 2025. The Data Safety Monitoring Board (DSMB) confirmed safety with no serious adverse events in the first cohort and recommended proceeding to the next cohort.
  • Type 1 Diabetes: Received FDA Orphan Drug Designation in March 2024. Patient recruitment for the Phase I/II trial was initiated in September 2023.
  • ImmCelz Platform: Validated through third-party studies showing reduced donor cell requirements and high purity.
• Liquidity: As of June 30, 2025, the company held $6.54 million in cash and US Treasuries. Management states this provides sufficient liquidity for operations, though the company continues to incur losses.
• Risks:
  • Minimal revenue generation and limited operating history.
  • Dependence on successful clinical trial outcomes and regulatory approvals.
  • Competition from well-funded companies with established sales forces.
  • Potential obsolescence of technology and supply chain disruptions.
• Unusual Items: The company recorded a non-cash adjustment of approximately $3.9 million to Additional Paid-in Capital related to the warrant inducement transaction (offsetting increase and decrease), resulting in no net impact on total equity.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $6.54 million cash balance against the operating cash burn of ~$2.75 million over six months.
• Clinical Trial Milestones: Confirm the timeline and enrollment status for the CELZ-201 ADAPT (back pain) and CREATE-1 (Type 1 Diabetes) trials.
• Revenue Recognition: Note that commercial revenue remains negligible ($3,000 for six months); verify if any new commercial contracts have been signed post-filing.
• Warrant Dilution: Review the terms of the 4.15 million outstanding warrants (exercise price ~$16.32 weighted average) and potential future dilution.
• Related Party Transactions: Review ongoing obligations under licensing agreements with related parties (e.g., CMH, Jadi Cell) for potential future cash or stock payments.